Purpose: The aim of this systematic review was to identify methods used to assess medication preferences in older adults and evaluate their advantages and disadvantages with respect to their applicability to the context of multimorbidity and polypharmacy. Material and Methods: Three electronic databases (PubMed, Web of Science, PsycINFO) were searched. Eligible studies elicited individual treatment or outcome preferences in a context that involved long-term pharmacological treatment options. We included studies with a study population aged ≥ 65 years and/or with a mean or median age of ≥ 75 years. Qualitative studies, studies assessing preferences for only two different treatments, and studies targeting preferences for life-sustaining treatments were excluded. The identified preference measurement methods were evaluated based on four criteria (time budget, cognitive demand, variety of pharmacological aspects, and link with treatment strategies) judged to be relevant for the elicitation of patient preferences in polypharmacy. Results: Sixty articles met the eligibility criteria and were included in the narrative synthesis. Fifty-five different instruments to assess patient preferences, based on 24 different elicitation methods, were identified. The most commonly applied preference measurement techniques were "medication willingness" (description of a specific medication with inquiry of the participant's willingness to take it), discrete choice experiments, Likert scale-based questionnaires, and rank prioritization. The majority of the instruments were created for disease-specific or context-specific settings. Only three instruments (Outcome Prioritization Tool, a complex intervention, "MediMol" questionnaire) dealt with the broader issue of geriatric multimorbidity. Only seven of the identified tools showed somewhat favorable characteristics for a potential use of the respective method in the context of polypharmacy. Conclusion: Up to now, few instruments have been specifically designed for the assessment of medication preferences in older patients with multimorbidity. To facilitate valid preference elicitation in the context of geriatric polypharmacy, future research should focus on suitable characteristics of existing techniques to develop new measurement approaches for this increasingly relevant population.
Introduction
Incorporating a patient's individual preferences into medical decision-making has improved treatment adherence and patient satisfaction. [1] [2] [3] Various medical disciplines, such as oncology, cardiology, or psychiatry, have examined preferenceoriented approaches to deliver optimized care. [4] [5] [6] Including the patient's priorities seems particularly favorable in clinical settings where sufficient evidence regarding the most effective treatment strategy is lacking. 7 The pharmacotherapy of older patients with multiple morbidities is characterized by relevant knowledge gaps due to a paucity of age-related and context-related data. 8 An uncritical adherence to disease-specific clinical practice guidelines in these patients will result in pronounced polypharmacy. 9 In numerous Western societies, prevalence rates between 10.0% and 27.4% have been reported for the chronic intake of 10 and more medicines ("excessive polypharmacy") in adults aged ≥ 65 years. 10−13 Polypharmacy increases the risk of adverse drug reactions 14 and drugdrug interactions. 15 It is independently linked with the number of incident falls experienced by older adults 16 as well as a decline in functionality. 17 In order to prevent or even reverse the negative effects of polypharmacy, recent articles advocate "deprescribing", 18, 19 which has been defined as "the process of withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing polypharmacy and improving outcomes". 20 Including the older patient's treatment preferences has been proposed as a technique to facilitate deprescribing. 21 Employing reliable and valid preference measurement methods is the prerequisite for evaluating patient preferences and integrating them into long-term health care decisionmaking. Instruments used in the geriatric setting need to be intelligible and operable for the older and potentially frail adults questioned. A recent systematic review aimed to identify tools suitable for eliciting treatment preferences in aged primary care patients with multimorbidity. 22 The authors found only one tool to be potentially relevant for recording outcome priorities in this context, concluding that there was an urgent need to further develop clinically applicable assessment strategies. 22 Acting on this need, we carried out a systematic review to identify preference measurement techniques that have been employed to determine the treatment priorities of older patients across various disease and non-disease specific settings, assess both their advantages and disadvantages with respect to their applicability in individuals with polypharmacy, and give recommendations for the development of future preference-based prescribing tools.
Material and Methods
The findings of this systematic review are presented in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. 23 
Search Strategy and Information Sources
We searched three electronic databases (PubMed, PsycINFO, and Web of Science) for studies reported in English or German. Abstracts published from the inception of the databases up to October 6, 2017 were considered for inclusion. We based our search strategy on modified versions of two published search strings for the identification of literature on geriatric medicine and patient preferences for treatment outcomes. 24, 25 Variations of terms relating to pharmacotherapy and health outcomes were added. The search strategy was adapted for each of the three databases. The complete search string for the PubMed database search is accessible in the Electronic Supplementary Material Table S1 . Reference lists of included articles were screened manually for potentially relevant articles.
Eligibility Criteria
Studies were eligible for inclusion if they aimed to identify individual treatment or outcome preferences or priorities of older adults by using a standardized, nonqualitative methodology. We defined preference as the relative "desirability" of a certain option. 26 The medical context of preference elicitation had to involve the pharmacological treatment of chronic conditions, either by directly evaluating preferences for specific medicines or their characteristics or by evaluating preferences for health outcomes potentially achieved with medicines. Studies were included if they addressed an aged population, defined by a cut-off for inclusion of ≥ 65 years. In case the eligibility criteria of individual studies did not exclude younger patients from participation, studies were suitable for inclusion if they reported a mean or median age of participants of ≥ 75 years. We also considered articles that focused on analyzing an aged population as a specific subgroup as stated in the abstract of the respective article. Full-text articles of abstracts not reporting age-related demographic data were only retrieved if the study context referred to diseases or medical problems characteristic of old age. We only included original research journal articles.
Owing to the particular nature and non-therapeutic quality of their setting, studies reporting patient preferences in the context of advance care planning and lifesustaining treatments were excluded. We also excluded studies that assessed preferences for merely two different treatments.
Study Selection
After removal of duplicates, one of the authors (AE) screened study titles and abstracts for eligibility. Full-text articles of potentially suitable abstracts were retrieved and assessed for inclusion independently by two reviewers (AE and AR). Disparities between the reviewing authors were resolved by discussion and through consultation with a third reviewer (SG).
In case of undetermined age-related eligibility, authors of the respective articles were contacted and asked to provide relevant age-related characteristics concerning the study population.
Data Collection Process and Analysis
Two authors (AE or AR) collected data from the included studies using a standardized data extraction form. Besides core study characteristics (year, location, study design, and sample size) extracted information comprised the following items: study population (age, cognitive status, and affective status), study context, preference measurement method used with, if applicable, the name of the specific instrument, and quality criteria including validity testing. Verification of all extracted data was carried out by the second reviewer (AE or AR).
Regarding the nomenclature of the identified preference elicitation techniques we relied primarily on the characterization of the method given by the respective authors. We coined the term "medication willingness" for all not otherwise specified instruments that gave a description of a certain medication and asked the study participants whether or not and, possibly, in what kind of circumstances they were willing to take that specific medication.
The data extraction form was complemented by a short assessment evaluating the adaptability of the identified preference measurement techniques to the context of aged patients with polypharmacy ("polypharmacy assessment"). We aimed at detecting a method that could be used in a routine clinical setting to individualize the medication of older adults with multiple chronic conditions based on the individual patient's preferences. This method would have to reflect the complexity of the context by integrating the majority of the multitude of treatment outcomes and treatment-related considerations innate to geriatric polypharmacy without neglecting the characteristics of the often physically and cognitively frail older population. Therefore, the assessment consisted of four methodological characteristics judged to be of relevance for preference elicitation instruments used in this setting: (1) time budget needed for health care workers to assess patient preferences, (2) level of cognitive demand imposed on the older respondent, (3) representation of a variety of pharmacological aspects including treatment options, and (4) link of recorded preferences with specific pharmacotherapeutic strategies. Each item was evaluated on a three-point scale with the categories "high", "intermediate", "low" (time budget, cognitive demand, and variety of pharmacological aspects) or "distinct", "moderate", "indistinct" (link with treatment strategies). Table 1 summarizes the criteria used to make the allocation to the respective categories. To assess the level of cognitive demand imposed on the respondent, we evaluated the number of cognitive steps needed as well as the assumed amount of time spent to reach an appropriate decision, which is an approach previously used in the optimization of experimental designs for conjoint analysis. 27 Two authors (AE and AR) independently completed the assessment for all 55 identified instruments, analyzing the preference methods as implemented by the respective instruments. Additionally, both reviewers evaluated if the respective preference measurement technique required the respondent to make trade-offs between competing medical problems. Disagreements were settled through consensus discussions. In the case of incomplete presentation of the preference elicitation instrument, authors of the respective articles were contacted and asked to provide additional information.
Due to the heterogeneity and mostly observational design of the eligible studies we did not conduct a metaanalysis but opted to present the collected data as an indepth narrative summary.
Quality Assessment
Owing to a lack of definite guidance on how to perform an appropriate quality assessment for preference-based studies, 28 the methodological quality of the included studies was evaluated by adapting four criteria from two previously published instruments for patient preference studies. 29, 30 Two reviewers (AE, AR) independently assessed whether (1) there was a well-defined question in relation to preferences, (2) the characteristics of the participants were clearly described, (3) the respective methods to assess preferences were clearly explained, and (4) the authors reported quality criteria in relation to the elicitation methods used. We expanded criterion number (2) (characteristics of the participants) to include data on the cognitive and affective status of the respondents. Any disparities were resolved by discussion (see Electronic  Supplementary Material Tables S2 and S3 ).
Results

Study Selection
Our database search identified 6786 citations; 358 articles were retrieved for full-text screening and 56 of these articles met the eligibility criteria. Four additional studies were identified by manually searching the reference lists of eligible articles. Figure 1 depicts the PRISMA flow diagram of the screening and selection process.
Study Characteristics
All articles included are listed in Table 2 . The majority (86.7 %) of the studies had a cross-sectional design. The research was performed in 12 different countries. Three (5.0%) of the eligible articles were published between 1994 and 1999, [31] [32] [33] 19 (31. 7%) between 2000 and 2009, [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] and 38 (63.3%) between 2010 and 2017 ( Table 2 ). The respective sample size ranged from 13 to 2637 participants. In four of the considered studies, the elicitation of patient preferences was only of minor interest. 39, [53] [54] [55] One study 56 was a follow-up study of a previously published cross-sectional study. 57 Four studies presumably used the same study sample. [58] [59] [60] [61] 
Study Populations
Thirty-nine studies met our age-related eligibility criteria by exclusively including adults aged 65 years and older, 32, 35, [37] [38] [39] 41, 42, [44] [45] [46] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] 16 by reporting a mean or median age ≥ 75 years, 31, 36, 40, 43, 47, 48, 61, [79] [80] [81] [82] [83] [84] [85] [86] [87] and 5 by systematically analyzing a subgroup within their overall study population aged 65 years or older. 33, 34, [88] [89] [90] Eleven studies indicated a mean or median age of 80 years or older. 42, 47, 49, 51, 52, 54, 56, 57, 71, 74, 79 Thirty-seven studies reported data regarding the cognitive status of their participants. 31, 32, 35, 36, [41] [42] [43] [44] 47, 49, [51] [52] [53] [55] [56] [57] [58] [59] [60] [61] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] 74, 75, 78, 80, 83, 84, 90 In 83.8 % of these studies Variety of pharmacological aspects represented by the method ▼ Low: Method elicits preferences for < 5 different pharmacological aspects (health outcomes, treatment options or procedural characteristics) ▬ Intermediate: Method elicits preferences for 5-10 different pharmacological aspects (health outcomes, treatment options or procedural characteristics) ▲ High: Method elicits preferences for > 10 different pharmacological aspects (health outcomes, treatment options or procedural characteristics) Link of recorded preferences with specific (pharmacological) treatment strategies ▼ Indistinct: Elicits preferences for very general outcomes or treatment characteristics; no obvious link to a specific treatment ▬ Moderate: Elicits preferences (eg for the treatment of specific bodily symptoms or for a related group of medications) that hint towards a larger selection of pharmacotherapeutic strategies or elicits preferences for treatment scenarios (lacking a detailed description of all relevant characteristics) ▲ Distinct: Attributes of the preference elicitation task directly linked with specific pharmacological treatment options during the design of the tool or elicits preferences for detailed and specific treatment scenarios participants were ineligible if one of the following criteria was present: some form of cognitive impairment such as a formal diagnosis of dementia, the failure to meet a specific cut-off on a standardized cognitive assessment, or cognitive problems as suspected by the investigator ( Table 2 ). Seventeen studies detailed the results of a standardized cognitive evaluation of their study population. 32, 36, 43, 51, 52, 55, 66, [68] [69] [70] [71] [72] 74, 78, 80, 83, 84 The participants' affective status was considered by 30 studies ( Table 2) .
Study Context
The majority of the identified 55 instruments were designed to assess patient preferences within a diseasespecific or context-specific setting. The most prevalent contexts were various types of cancer (9 tools), 33, 41, 48, 55, 66, 72, 86, 90 mental health issues including depression (7 tools), 43, 45, 67, 71, 73, 75, 82, 83 cardiovascular prevention (7 tools), 46, 47, 60, 61, 63, 74, 88 stroke prevention in atrial fibrillation (5 tools), 32, 42, 44, 50, 80 and age-related macular degeneration (4 tools). 79, 81, 85, 87 Only three tools were designed for the greater context of multimorbidity: the Outcome Prioritization Tool, 56,57,59,60,65 the complex intervention "PrefCheck" combining a comprehensive geriatric assessment ("STEP assessment") with a health priority evaluation, [68] [69] [70] 78 and the "MediMol" questionnaire. 53 The latter, however, focuses on the monitoring of various medication-related problems and includes only a minor preference assessment. Four tools concentrated on a specific sub-context of multimorbidity, such as the tradeoffs between present and future health (2 tools) 58, 59 or the trade-offs between a specific subset of competing health outcomes in multimorbidity (2 tools). 51, 52, 63 One instrument evaluated a set of general health outcomes for the medical care of older adults. 62
Methods to Assess Patient Preferences
The most prevalent preference elicitation methods among the 55 identified instruments were "medication willingness" (9 instruments), discrete choice experiments (7 instruments), and Likert scale-based questionnaires (6 instruments) (Tables 2 and 3 ). Six instruments used ranking exercises, two in combination with a preceding choice of the most relevant options by the participant and one in combination with a Likert scale. 43, 62, 71, 75, 77, 82, 83 A direct choice between different treatment options was employed by four instruments, one using an additional questionnaire. 48, 54, 66, 73 The time trade-off technique and questionnaires were used by three instruments respectively. 35, 37, 38, 53, 67, 72 Two instruments each used adaptive conjoint analysis, 76, 89 the probability trade-off technique, 46, 90 or an individualized decision analysis. 46, 50 Single instruments applied the analytical hierarchy process, 81 a complex intervention, 68-70,78 traditional conjoint analysis, 79 the format of a decision aid, 44 the feeling thermometer, 40 maximum difference scaling, 77 paired comparisons, 49 switch-point vignettes, 33 a visual analogue scale, 59, 60 and willingness to pay. 84 One specific health outcome prioritization tool was evaluated by five different studies. 56, 57, 59, 60, 65 Test Quality of the Instruments to Assess Patient Preferences
The column "quality criteria" in Table 2 gives a short summary regarding the test quality for each of the different instruments as reported in the respective articles. Owing to the large number of studies using literature searches and expert opinions during the design of the preference tools, data on content validity were omitted in favor of further validity or reliability assessments. Five studies evaluated the construct validity of the respective tools by measuring their agreement with other preference instruments or with predefined hypotheses. 40, 58, 60, 65, 84 All seven discrete choice experiments and the traditional conjoint analysis used additional choice scenarios to test the participants' understanding of the task as well as the consistency of their answers. 51, 64, 79, 80, [85] [86] [87] [88] One study targeted criterion validity by inquiring the patients' satisfaction with the treatment that was selected based on the results of the preference elicitation. 48 Nine studies applied qualitative research to aid the interpretation of the quantitative results of the respective preference task. 42, 43, 57, 59, 65, 76, 81, 87, 90 Polypharmacy Assessment
The results of our "polypharmacy assessment" are detailed in Table 3 . The majority of the instruments (70.9 %) were exclusively tested in interview mode and thus claimed a high amount of time of the respective health care worker. Eighteen instruments were judged to impose a low cognitive demand on the older respondent, 20 to impose an intermediate, and 15 to impose a high cognitive demand. Tools that were rated to present a low cognitive demand primarily used Likert scales, other questionnaires, a direct choice, or ranking exercises with few attributes as their methodological approach. Instruments with a high cognitive demand asked of the respondent to simultaneously trade-off between a large number of attributes or several probability calculations, for example within more complex conjoint analysis-based experiments or during time trade-off tasks. Only three tools evaluated more than 10 pharmacological attributes and were rated to represent a broad variety of aspects. 35, 62, [68] [69] [70] 78 The majority of the instruments provided an either distinct (28 tools) or moderate (22 tools) link with a specific drug therapy. The advantages and disadvantages of the various methods showed opposing trends: no tool with a low cognitive demand and only one tool 35 that represented a high variety of pharmacological aspects was rated to provide a distinct link with a specific treatment strategy (Table 3) .
No tool was given an ideal rating, and none of the instruments scored more than two positives out of the four ratings. Only seven tools scored at least one positive rating and no negative rating for the criteria "cognitive demand", "variety of pharmacological aspects", and "link with treatment strategies": one analytical hierarchy process, 81 the complex intervention "PrefCheck", [68] [69] [70] 78 two discrete choice experiments, 80, 87 the maximum difference scaling, 77 one example of "medication willingness", 42 and the "MediMol" questionnaire 53 ( Table 3 ). The analytical hierarchy process, maximum difference scaling as well as discrete choice experiments are well-established methods to measure preferences. 77, 80, 81, 87 "PrefCheck" is a complex intervention, specifically designed to assess health priorities in older primary care patients. 68 It is based on a validated comprehensive geriatric assessment. 68 No data regarding the validity or reliability of the instrument have been reported for the "MediMol" questionnaire. 53 
Methodological Quality of Included Studies
The results of the quality assessment are depicted in the Electronic Supplementary Material Table S3 . Four studies failed to give a comprehensive description of the preference measurement method used. 36, 48, 66, 89 
Discussion
To our knowledge, this is the first review to both systematically identify methods used to assess medication preferences in older adults and to rate their potential in regard to preference elicitation within the context of polypharmacy. We aimed at determining methods that could support an individualized prescribing process by including the patient's medication preferences. We identified 55 different instruments that have been applied to evaluate patient preferences in old age pharmacotherapy, based on 24 different methods to determine preferences. Apart from "medication willingness", a term that we originally coined to specify a group of not otherwise characterized instruments that directly elicited the participant's willingness for the use of a certain medication, we found that discrete choice experiments, Likert scale-based ratings, and ranking exercises were the most commonly employed elicitation methods in older adults. This finding is in line with data from a non-age-specific investigation on the integration of patient preferences in clinical decision-making that listed rating scales, ranking exercises as well as discrete choice experiments amongst the most prevalent methods. 91 Only a minority of the eligible instruments targeted the context of multimorbidity-related polypharmacy. In addition to the Outcome Prioritization Tool identified in a review on preference elicitation in older primary care patients with multiple conditions, 22 we found two further tools that were specifically designed to assess multimorbidity-related patient preferences. The complex intervention "PrefCheck" combines the geriatric "STEP assessment" with a Likert scale-based individual health priority evaluation by the patients and their general practitioners followed by a priority-setting consultation. It focusses on general health problems, with medicationrelated aspects being one part of an extensive evaluation including social and financial issues. Because it is based on a comprehensive geriatric assessment, this approach is time-consuming but might be practicable in settings routinely collecting the respective data. The reliability of the "PrefCheck"-related health priority evaluation is yet to be determined. 68 The second additional instrument identified, the "MediMol" questionnaire, does not primarily focus on measuring patient preferences but incorporates the elicitation of universal health priorities into the assessments of various medication-related issues. Neither the "PrefCheck" intervention nor the "MediMol" questionnaire allow for trade-offs between competing health outcomes.
To identify further preference measurement techniques that could serve as a basis for future tools to allow for preference-based individualized prescribing in polypharmacy, we conducted a thorough evaluation of all 55 identified preference elicitation instruments and analyzed their advantages and disadvantages with the help of four relevant characteristics ("time budget", "cognitive demand", "variety of pharmacological aspects", and "link with treatment strategies"). In order to meet the time constraints imposed by routine medical practice, tools for the measurement of patient preferences should reduce the amount of time the physician needs to invest in preference elicitation. However, the vast majority of the instruments in our review were tested in interview mode and as such did not offer any time-saving benefits. To allow for large-scale application outside of separately funded study settings, future tools need to be simple and usable to be selfadministered by the older patient and future research should particularly address the feasibility of selfadministration. Alternatively, one might advocate integrating the standardized elicitation of patient preferences into the comprehensive geriatric assessment, thereby providing a time frame for this important task within the routine geriatric setting.
Besides the "PrefCheck" intervention and the "MediMol" questionnaire only five other instruments showed no negative rating and at least one positive rating for the remaining three criteria "cognitive demand", "variety of pharmacological aspects", and "link with treatment strategies". Two discrete choice experiments were among these five favorable tools. 80, 87 Typical for this method, these two instruments were designed to directly link the measured patient preferences to a specific drug therapy, revealing one of the advantages of this approach. Both tools balanced the cognitive demand of their choice tasks and the number of attributes within the choice sets by defining simple attribute levels, refraining from confronting the participants with risk reduction percentages, and using visual aids such as pictographs or a clear questionnaire layout. The cognitive demand of a discrete choice experiment is expected to increase with the number of attributes included in the choice task and the maximum number of attributes to consider is generally given as six to seven. 92 This restricted number of health outcomes or other pharmacotherapy-related aspects that could be represented in the instrument seems to limit the profitable use of the method in multimorbidity-related polypharmacy. However, future tools aiming at preference-based individualized prescribing might combine the actual discrete choice experiment with an individual preselection of the relevant attributes by the patient. The indirect scenariobased approach of preference measurement is thought to be challenging for the respondent and none of the seven discrete choice experiments in this review was rated to impose a low cognitive demand on the participant. However, research indicates that simple discrete choice experiments with a reduced number of choice sets might be successfully completed even by older adults with mild cognitive impairment. 93 The cognitive demand for the older participant and its impact on the feasibility of the instruments need to be evaluated in more depth in order to clarify whether the potential of this popular method of preference elicitation is developable or limited in old-age polypharmacy. Similar considerations might apply to the analytical hierarchy process 81 and the maximum difference scaling 77 which, according to the standards of our assessment, impose an intermediate cognitive demand on the respondent. To date, little evidence in regard to the measurement of patient preferences exists for either of these methods. The last approach rated as possibly favorable in polypharmacy, a version of "medication willingness", 42 differs from the aforementioned techniques in that it would require developing a reasoned algorithm of adding or altering variables of a medication scenario and repeatedly asking the patients whether or not they would be willing to take the specified drug therapy.
Interestingly, the Outcome Prioritization Tool, which was previously identified as potentially relevant for measuring treatment preferences in older patients with multiple conditions, 22 did not tend towards an overall favorable rating on our "polypharmacy assessment". This evaluation was based on the time-consuming design as an interview tool, the intermediate level of cognitive demand owing to the need of multiple trade-offs, the limited number of health outcomes incorporated in the instrument, and a moderate to unclear link of the recorded priorities with a specific drug therapy. The latter evaluation is substantiated by the results of a recent study that suggested that primary care physicians might find it difficult to translate the patient's preference for the general outcome "maintaining independence" to a certain change in his or her medication. 56 Several limitations of this systematic review should be addressed. Despite our comprehensive search strategy, potentially eligible articles might not have been identified. The four methodological criteria for the "polypharmacy assessment" were developed by our research group instead of being derived from a thorough literature review and accompanying expert interviews. Due to the unique characteristics of pharmacotherapy we limited our eligibility criteria to exclude studies without any long-term drug therapy-related aspects. It might be possible, that published methods assessing patient preferences within non-pharmacological contexts, eg surgery, could also offer some potential in relation to preference elicitation in polypharmacy.
Conclusion
To our knowledge, this is the first systematic review offering a comprehensive overview of instruments used to assess patient preferences in old age pharmacotherapy. No ideal method for practicable and valid elicitation of patient preferences in the context of geriatric polypharmacy could be identified. By evaluating the existing preference measurement instruments on four criteria salient for successful preference-based individualized prescribing in polypharmacy, the findings of this systematic review can guide future research in polypharmacy-related patient preferences and provide relevant information for the development of new and more appropriate measurement approaches.
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